Phase II Clinical Study of LTC004 in Patients With Advanced Sarcoma

Summary

This is a phase II clinical study to evaluate the safety, tolerability and preliminary antitumor activity of LTC004 in patients with locally advanced or metastatic sarcoma；Enrollment of 10 evaluable subjects in Phase I. If ≥2 subjects experience objective remission or SD lasting \>12 weeks, proceed to Phase II to enroll an additional 20 evaluable subjects to further evaluation of the safety and efficacy of LTC004

Timeline

Start

2024-04-26

Primary completion

2025-12-28

Completion

2025-12-28

Drugs

Indications